Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study tracks immune effects of NMOSD drug over years

NCT ID NCT06180278

Ongoing Disease control Sponsor: Amgen Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at the long-term safety of inebilizumab (UPLIZNA) in people with neuromyelitis optica spectrum disorder (NMOSD). Researchers will measure immune markers like immunoglobulins and B-cells in 32 participants during treatment and after stopping. The goal is to understand how the drug affects the immune system over time and how it recovers after discontinuation.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
inebilizumab (UPLIZNA)
What this could lead to
If successful, this study could confirm that long-term use of inebilizumab is safe and help doctors understand when to stop or continue treatment for NMOSD.
What could go wrong
This is a small, open-label study with only 32 participants, so results may not apply to everyone. It focuses on safety, not on whether the drug works better than other options.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NEUROMYELITIS OPTICA SPECTRUM DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuromyelitis optica

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NEUROMYELITIS OPTICA SPECTRUM DISORDER

Contacts and locations

Locations

  • Baylor College of Medicine

    Houston, Texas, 77030-4202, United States

  • Khon Kaen University, Srinagarind Hospital - Division of Neurology, Depart

    Khon Kaen, 40002, Thailand

  • M.A.-Lek A.M. Maciejowscy S.C. Centrum Terapii SM

    Katowice, Silesian Voivodeship, 40-751, Poland

  • National Cancer Center - Neurology Clinic

    Goyang-si, Gyeonggido [Kyonggi-do], 10408, South Korea

  • Prince of Wales Hospital (PWH) - The Chinese University of Hong Kong (CUHK) - Ophtalmology

    Hong Kong, 0000, China

  • Samsung Medical Center - Pediatric Neurology

    Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, 6351, South Korea

  • Seoul National University Hospital

    Seoul, Seoul Teugbyeolsi [Seoul-T'ukp, 03080, South Korea

  • Szegedi Tudományegyetem, à OK, Szent-Györgyi Albert Klinikai Központ - Neurológiai Osztály

    Szeged, Csongrád megye, 6725, Hungary

  • Uniwersyteckie Centrum Kliniczne WUM - Oddzial Kliniczny Neurologii

    Warsaw, Masovian Voivodeship, 02-057, Poland

  • Vseobecna fakultni nemocnice v Praze - Neurologicka klinika

    Prague, 128 21, Czechia

  • Wayne State University School of Medicine

    Detroit, Michigan, 48201-2153, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.